Article By:
NASDAQ GlobeNewswire
Thursday, July 16, 2020 7:15 PM EDT
Cytokinetics, Incorporated today announced the pricing of an underwritten public offering of 7,291,667 shares of its common stock at a price to the public of $24.00 per share, before underwriting discounts and commissions.
In this article: CYTK
Is Gilead Sciences About To Buy Vertex For $45 Billion?
What's your take on $CYTK?
Small Cap Best & Worst Report - October 9, 2014
Yes, $CYTK is a pos. If it gets over 4 again, I'm out.